Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

At this time, all participants are in a listen-only ... for COPD through a recently launched direct-to-consumer campaign. Libtayo in the U.S. grew 21% compared to the first quarter of last year ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

"We have made meaningful progress across our pipeline so far in ... an sBLA to the FDA and a regulatory application in the EU for Libtayo (cemiplimab) in adjuvant CSCC based upon data from a ...

We are also working to ensure our four blockbuster medicines reach even more patients who could benefit, with year-to-date progress including ... in the EU for Libtayo (cemiplimab) in adjuvant ...

“Our corporate progress in Q1 has matched the pace of our clinical progress ... Clinical Trial Supply Agreement Announced with Regeneron for Libtayo (cemiplimab): In February, Immuneering announced a ...

Key topics include results from the Phase 3 trial of Libtayo for high-risk cutaneous ... like linvoseltamab and odronextamab is still in progress, highlighting uncertainty in their future success ...